The Bladder Utility Symptom Scale (BUSS): A Novel Patient-Reported Outcome Instrument in Bladder Cancer.
J Urol. 2018 Mar 09;:
Serum miRNA predicts viable disease post-chemotherapy in testicular non-seminoma germ cell tumor patients.
J Urol. 2018 Feb 20;:
A New Model to Predict Benign Histology in Residual Retroperitoneal Masses After Chemotherapy in Nonseminoma.
Eur Urol Focus. 2018 Feb 07;:
Recommendations for followup of stage I and II seminoma: The Princess Margaret Cancer Centre approach.
Can Urol Assoc J. 2017 Dec 01;:
Analysis of Margin Classification Systems for Assessing the Risk of Local Recurrence After Soft Tissue Sarcoma Resection.
J Clin Oncol. 2018 Jan 18;:JCO2017746941
Pract Radiat Oncol. 2018 Jan 03;:
Int J Radiat Oncol Biol Phys. 2017 Nov 01;99(3):511
Use of hydrogel spacer for improved rectal dose-sparing in patients undergoing radical radiotherapy for localized prostate cancer: First Canadian experience.
Can Urol Assoc J. 2017 Dec;11(12):373-375
Curative Radiation Therapy at Time of Progression Under Active Surveillance Compared With Up-Front Radical Radiation Therapy for Prostate Cancer.
Int J Radiat Oncol Biol Phys. 2017 Nov 01;:
Long-Term Quality of Life of Retroperitoneal Sarcoma Patients Treated with Pre-Operative Radiotherapy and Surgery.
Cureus. 2017 Oct 11;9(10):e1764